Physician

Brajesh Bhatla, M.D.

According to 2025 Medicare claims, Brajesh Bhatla, M.D. (NPI: 1821045600) practices nephrology in the Brownsville-Harlingen, TX market, with the plurality of this provider's patient population coming from Cameron, TX. This provider's primary affiliated billing organization is BRAJESH BHATLA MD PA (NPI: 1821044108; TIN: 201195084) and primary practice location at 78550-9290.

Bhatla's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 624 traditional Medicare patients, billed 9,789 HCPCS/CPT codes, and received $722,005 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 8,484 prescription claims across 913 beneficiaries totaling $1,999,366 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). DME data shows 239 claims. Open Payments data shows 32 records totaling $609. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $1,146,525 to $722,005. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and declined steadily, from $6,805 to $3,657.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,064	19,144	$1,146,525
2016	1,090	20,585	$1,240,374
2017	1,146	20,436	$1,275,109
2018	1,145	18,901	$1,291,742
2019	1,143	18,825	$1,312,986
2020	1,061	17,732	$1,361,938
2021	967	15,306	$1,211,572
2022	785	13,102	$990,383
2023	710	10,641	$781,128
2024	624	9,789	$722,005

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	854	13,034	$1,483,126
2016	843	13,592	$2,171,558
2017	838	12,710	$3,130,386
2018	865	11,260	$2,343,252
2019	863	10,207	$2,101,204
2020	882	9,626	$1,745,335
2021	842	8,989	$1,678,058
2022	871	8,634	$1,944,062
2023	888	8,284	$2,191,952
2024	913	8,484	$1,999,366

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	71	442	$23,194
2016	70	534	$20,828
2017	82	520	$18,940
2018	71	466	$16,511
2019	46	405	$16,546
2020	13	507	$20,966
2021	24	441	$10,671
2022	11	437	$10,680
2023	N/R	325	$6,627
2024	N/R	239	$5,449

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	370	1,557	$95
36415	Insertion of needle into vein for collection of blood sample	287	579	$9
82044	Urine microalbumin (protein) analysis	291	1,123	$6
82570	Creatinine level to test for kidney function or muscle injury	291	1,120	$5
85018	Blood count, hemoglobin	265	872	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	167	6,628	$593,498
Farxiga	Dapagliflozin Propanediol	545	19,116	$337,621
Sevelamer Carbonate	Sevelamer Carbonate	514	26,239	$185,398
Rybelsus	Semaglutide	138	5,040	$154,424
Auryxia	Ferric Citrate	39	2,090	$88,713

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7502	Cyclosporine, oral, 100 mg	N	N/R	12	$1,238
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	45	$977
J7515	Cyclosporine, oral, 25 mg	N	N/R	14	$964
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	57	$803
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	41	$715

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	32	$609	Bayer Healthcare Pharmaceuticals Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Brajesh Bhatla, M.D.?

Tedicare shows public-source Medicare data for Brajesh Bhatla, M.D. (NPI 1821045600), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Brajesh Bhatla, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Brajesh Bhatla, M.D.?

Brajesh Bhatla, M.D. is linked to BRAJESH BHATLA MD PA (billing NPI 1821044108) in the available physician profile data.

Does Brajesh Bhatla, M.D. have Open Payments data?

Brajesh Bhatla, M.D. has 32 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.